SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4188)5/2/1998 4:56:00 PM
From: Mike Hagerty  Read Replies (1) | Respond to of 6136
 
In Dick Davis Digest this week end:

"Agouron Pharmaceutical (AGPH 36 OTC) reported financial results for their fiscal 1998 third quarter," notes Jim McCamant (Medical Technology Stock Letter). "Net income was $0.41 per share compared to a net loss of $0.18 per share in 1997. Sales of Viracept continue to increase.
Since the drug was launched in March of last year, Viracept sales totaled over $300 million. This makes Viracept number one all-time in terms of the first twelve months of sales of any product from a biotech company. Agouron is a buy under 40."




To: Steve Fancy who wrote (4188)5/4/1998 11:51:00 AM
From: Steve Fancy  Read Replies (2) | Respond to of 6136
 
Looks like John Abelson sold 20K shares on 03/05/98. There are actually 2 entries for 20K each. Don't know if that's an error or he sold 40K shares. Also, the shares remaining field is blank on both...don't know what that means. As far as I can tell, last reported transaction, he still held 47K shares.

sf



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News